Komori
Presentation materials for financial results4568DAIICHI SANKYO COMPANY,LIMITEDPharmaceuticals

Financial Results Briefing Materials for the First Quarter of Fiscal 2026

In the first quarter of FY2026, revenue increased on growth in key products and the weaker yen, while operating profit and net profit declined due to higher cost of sales, SG&A expenses, R&D expenses and business reorganization costs. The full-year forecasts were revised upward by ¥60 billion for revenue and ¥5 billion for operating profit, while profit attributable to owners of the parent was revised downward by ¥9 billion.

Worth reading
84Important
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
600
¥100 million (change from the previous forecast for full-year revenue)
Wording
Avoiding a definitive answer
How definitive the wording is.

Contents of this document

Presentation materials for financial resultsFY2026 First Quarter8 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales5,747 Hundreds of millions of yen+21.1%
Operating profit851 Hundreds of millions of yen-12.0%
Ordinary income913 Hundreds of millions of yen
Net income686 Hundreds of millions of yen-19.7%
Selling, general and administrative expenses2,260 Hundreds of millions of yen
Results for the three months of the current quarter
Revenue
5,747 Hundreds of millions of yen+21.1%
Operating profit
851 Hundreds of millions of yen-12.0%
Profit before tax
913 Hundreds of millions of yen
Profit for the year attributable to owners of the parent
686 Hundreds of millions of yen-19.7%
Quarterly EPS
¥37.72-18.1%
Full-year earnings forecast
Revenue
23,400 Hundreds of millions of yen
Cost of sales
5,500 Hundreds of millions of yen
Selling, general and administrative expenses
9,300 Hundreds of millions of yen
Research and development costs
5,000 Hundreds of millions of yen
Core operating profit
3,600 Hundreds of millions of yen
Operating profit
3,200 Hundreds of millions of yen
Profit before tax
3,340 Hundreds of millions of yen
Profit for the year attributable to owners of the parent
2,510 Hundreds of millions of yen
EPS
¥137.94
Progress against full-year forecast　通期の予想に対して、いまどこまで進んだかの割合です。
Enhertu® global product sales25.4%
Datroway® global product sales18.5%
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Revenue
Japan Business Unit and other7
Oncology Business Unit478
American Regent Unit110
EU Specialty Business Unit22
ASCA Business Unit47
Upfront and milestone payments152
Foreign Exchange Effects419
Operating profit
Revenue1,001
Cost of sales385
Selling, general and administrative expenses459
Research and development costs95
Non-core income and expenses179
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
USD/JPY from the second quarter onward¥155
EUR/JPY from the second quarter onward¥180
New initiatives
  • Plan to begin a FIH trial of DS1025 in solid tumors in the first half of FY2026
  • Plan to begin the Phase 3 TROPION-Urothelial04 trial of Datroway® in combination with rilvegostomig in the second half of FY2026
  • Policy of identifying multiple Next BGTs by FY2030
Key KPIsA metric the company considers important as a management benchmark.
  • Enhertu® global product sales2,192 Hundreds of millions of yen
    Year on year against the same period last year+41.2%
  • Datroway® global product sales206 Hundreds of millions of yen
    Year on year against the same period last year+289.9%
  • Cumulative number of patients treated with Datroway®7,000 people, approx.
    Year on year against the same period last yearApproximately 1.4x the previous quarter
  • Percentage of metastatic breast cancer patients for whom treatment options can be offered90 Over %
  • Datroway® confirmed ORR in TNBC62.5 %
  • Confirmed ORR for chemotherapy29.3 %
  • ORR for the TROPION-Urothelial04 combination therapy68.2 %
  • 12-month PFS rate for the TROPION-Urothelial04 combination therapy73.5 %
Segment results
  • Japan Business
    Revenue1,200 Hundreds of millions of yen (YoY -3.9%)
  • Daiichi Sankyo Healthcare
    Revenue226 Hundreds of millions of yen
  • Oncology Business
    Revenue1,974 Hundreds of millions of yen
  • American Regent
    Revenue422 Hundreds of millions of yen
  • EU Specialty Business
    Revenue747 Hundreds of millions of yen
  • ASCA (Asia and Latin America) Business
    Revenue687 Hundreds of millions of yen
Medium-term management plan targets
Fifth medium-term management plan
Revenue¥1.6 trillion
Oncology revenue¥600 billion or more
Core operating profit margin before R&D expenses40%
ROE16% or higher
DOE8% or higher
FY2025 actual
Revenue¥2.123 trillion
Oncology revenue¥954 billion
Core operating profit margin before R&D expenses40.1%
ROE16.9%
DOE8.7%
Financial targets
ROE
Target16% or higher
Actual results16.9%
DOE
Target8% or higher
Actual results8.7%
Market Size / Share
Percentage of metastatic breast cancer patients for whom treatment options can be offeredAt least 90%
Datroway® patient share in the US EGFR-mutated NSCLC 3L+ market1st place
Contents of this document
ItemDetails
Document typePresentation materials for financial results
Fiscal Period CoveredFY2026 First Quarter
Net Sales5,747 Hundreds of millions of yen (YoY +21.1%)
Operating profit851 Hundreds of millions of yen (YoY -12.0%)
Ordinary income913 Hundreds of millions of yen
Net income686 Hundreds of millions of yen (YoY -19.7%)
Selling, general and administrative expenses2,260 Hundreds of millions of yen
Results for the three months of the current quarterRevenue 5,747 Hundreds of millions of yen (YoY +21.1%) / Operating profit 851 Hundreds of millions of yen (YoY -12.0%) / Profit before tax 913 Hundreds of millions of yen / Profit for the year attributable to owners of the parent 686 Hundreds of millions of yen (YoY -19.7%) / Quarterly EPS ¥37.72 (YoY -18.1%)
Full-year earnings forecastRevenue 23,400 Hundreds of millions of yen / Cost of sales 5,500 Hundreds of millions of yen / Selling, general and administrative expenses 9,300 Hundreds of millions of yen / Research and development costs 5,000 Hundreds of millions of yen / Core operating profit 3,600 Hundreds of millions of yen / Operating profit 3,200 Hundreds of millions of yen / Profit before tax 3,340 Hundreds of millions of yen / Profit for the year attributable to owners of the parent 2,510 Hundreds of millions of yen / EPS ¥137.94
Progress against full-year forecastEnhertu® global product sales 25.4% / Datroway® global product sales 18.5%
Segment resultsSegment Japan Business / Revenue 1,200 Hundreds of millions of yen (YoY -3.9%), Segment Daiichi Sankyo Healthcare / Revenue 226 Hundreds of millions of yen, Segment Oncology Business / Revenue 1,974 Hundreds of millions of yen, Segment American Regent / Revenue 422 Hundreds of millions of yen, Segment EU Specialty Business / Revenue 747 Hundreds of millions of yen, Segment ASCA (Asia and Latin America) Business / Revenue 687 Hundreds of millions of yen
Breakdown of Factors Affecting the ChangeRevenue Japan Business Unit and other 7 / Oncology Business Unit 478 / American Regent Unit 110 / EU Specialty Business Unit 22 / ASCA Business Unit 47 / Upfront and milestone payments 152 / Foreign Exchange Effects 419 / Operating profit Revenue 1,001 / Cost of sales 385 / Selling, general and administrative expenses 459 / Research and development costs 95 / Non-core income and expenses 179
Key KPIsIndicator name Enhertu® global product sales / Value 2,192 Hundreds of millions of yen / Year on year against the same period last year +41.2%, Indicator name Datroway® global product sales / Value 206 Hundreds of millions of yen / Year on year against the same period last year +289.9%, Indicator name Cumulative number of patients treated with Datroway® / Value 7,000 people, approx. / Year on year against the same period last year Approximately 1.4x the previous quarter, Indicator name Percentage of metastatic breast cancer patients for whom treatment options can be offered / Value 90 Over % / Year on year against the same period last year Not disclosed, Indicator name Datroway® confirmed ORR in TNBC / Value 62.5 % / Year on year against the same period last year Not disclosed, Indicator name Confirmed ORR for chemotherapy / Value 29.3 % / Year on year against the same period last year Not disclosed, Indicator name ORR for the TROPION-Urothelial04 combination therapy / Value 68.2 % / Year on year against the same period last year Not disclosed, Indicator name 12-month PFS rate for the TROPION-Urothelial04 combination therapy / Value 73.5 % / Year on year against the same period last year Not disclosed
Assumptions Underlying the Business OutlookUSD/JPY from the second quarter onward ¥155 / EUR/JPY from the second quarter onward ¥180
Medium-term management plan targetsFifth medium-term management plan Revenue ¥1.6 trillion / Oncology revenue ¥600 billion or more / Core operating profit margin before R&D expenses 40% / ROE 16% or higher / DOE 8% or higher / FY2025 actual Revenue ¥2.123 trillion / Oncology revenue ¥954 billion / Core operating profit margin before R&D expenses 40.1% / ROE 16.9% / DOE 8.7%
Financial targetsROE Target 16% or higher / Actual results 16.9% / DOE Target 8% or higher / Actual results 8.7%
Market Size / SharePercentage of metastatic breast cancer patients for whom treatment options can be offered At least 90% / Datroway® patient share in the US EGFR-mutated NSCLC 3L+ market 1st place
New initiativesPlan to begin a FIH trial of DS1025 in solid tumors in the first half of FY2026, Plan to begin the Phase 3 TROPION-Urothelial04 trial of Datroway® in combination with rilvegostomig in the second half of FY2026, Policy of identifying multiple Next BGTs by FY2030
Items this document does not state (13)
Gross Profit MarginOperating profit marginSelf-assessment against the planUnit price and quantity metricsNumber of stores and locationsNumber of employeesRisk amount incorporated into the outlookAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Revenue increased in the first quarter, driven by sales growth for Enhertu® and Datroway® and foreign exchange effects. Operating profit declined due to higher cost of sales and profit-sharing expenses accompanying revenue growth, increased R&D investment, and costs related to the reorganization of the EU Specialty Business Unit. The full-year revenue forecast was revised upward due to the revised assumed exchange rates from the second quarter onward and US Enhertu® product sales exceeding expectations. The operating profit forecast was revised upward due to the reversal of the provision for compensation related to the cancellation of investment in the Odawara Plant.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Financial Results Briefing Materials for the First Quarter of Fiscal 2026 | DAIICHI SANKYO COMPANY,LIMITED (4568) timely disclosure | Komori